Interleukin-6 signal transducer
IL6STproteingp130 transduces IL-6 trans-signaling, amplifying monocyte recruitment and atherosclerotic inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleIL-6 trans-signaling co-receptor driving pro-inflammatory monocyte recruitment and plaque destabilization.
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000134352
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I28
C — confounder / Type-II55
A — assay feasibility72
E — evidence strength21
T1DI (composite)5
Specificity differential (R−C)-26.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(3)
- Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk.Vascular pharmacology · 2023 · PMID 37634789 · doi
- The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI.Mediators of inflammation · 2021 · PMID 34135690 · doi
- Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130.Mediators of inflammation · 2017 · PMID 28250574 · doi